



## NEWS RELEASE

### FOR IMMEDIATE RELEASE

**Media Contact:**

Susan Heins, Pure Communications, Inc.  
864-286-9597

### **NinePoint Medical Presents New Clinical Data on NvisionVLE at Digestive Disease Week**

*Data Demonstrates Feasibility of Imaging Barrett's Esophagus with VLE Technology*

**Cambridge, Mass. – May 21, 2013** – [NinePoint Medical, Inc.](#), an emerging leader in the development of medical devices for advanced optical imaging, today announced that findings from two clinical trials of its proprietary advanced optical coherence tomography (OCT) based NvisionVLE™ Imaging System are being presented during [Digestive Disease Week](#) (DDW), May 18-21, 2013, in Orlando, Fla. The research, from clinical trials performed at the Mayo Clinic in Rochester, Minn. and Jacksonville, Fla., and the Kansas City Veteran's Affairs Hospital, and in conjunction with Massachusetts General Hospital, was the subject of eight presentations at DDW highlighting the feasibility and diagnostic utility of the Volumetric Laser Endomicroscopy (VLE) technology for imaging esophageal tissue and Barrett's esophagus.

Findings from the presentation titled, "Can Volumetric Laser Endomicroscopy Detect Dysplasia in Barrett's Esophagus?" were presented Sunday, May 18. This research, led by Kenneth Wang, M.D., director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic at the Mayo Clinic, explored the correlation between dysplasia detected by advanced OCT and histopathological analysis in patients suffering from Barrett's esophagus, a known precursor to esophageal adenocarcinoma. The data demonstrated a dysplasia detection rate in patients with Barrett's esophagus of 95% using the NvisionVLE Imaging System.

Today, a presentation titled "Feasibility of Using a Novel Imaging Technique in Patients with Barrett's Esophagus: 3 Dimensional Volumetric Laser Endomicroscopy" will be presented. In this study, researchers evaluated the feasibility and safety of VLE imaging in patients with Barrett's esophagus. Data show the VLE procedure was performed successfully in all 74 patients evaluated, with no serious adverse events. The average time for the VLE procedure was 17.4 minutes, and preliminary results demonstrate that all patients with confirmed high-grade dysplasia were detected with the VLE system.

#### **About The NvisionVLE™ Imaging System**

NinePoint Medical's proprietary NvisionVLE Imaging System will enable physicians and pathologists to endoscopically view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at better than 10 micron resolution. Utilizing an advanced form of Fourier-domain optical coherence tomography (FD-OCT) also known as OFDI (optical frequency-domain imaging), NvisionVLE provides treating physicians and pathologists with cross-sectional, volumetric digital images of a patient's organ – including below the surface of

the tissue, over very large areas. This imaging information can be used to aid clinician decision-making relative to biopsy placement or treatment planning. The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization. The safety and effectiveness of this device for diagnostic analysis (i.e. differentiating normal versus specific abnormalities) in any tissue microstructure or specific disease has not been evaluated.

Developed at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH), NinePoint licensed the technology in 2010 as part of the largest intellectual property agreement for medical device technology in the hospital's history.

**About NinePoint Medical, Inc.**

NinePoint Medical is positioned to improve patient care through the development of medical devices that enable high resolution in-vivo imaging. The Company was founded on the ideal of convergence, of developing products that could bring together access, diagnosis and treatment. Founded in 2009 with an initial Series A of \$33 million, the Company licensed the fundamental optical coherence tomography (OCT) technology from Massachusetts General Hospital (MGH) in 2010 and received its first 510(k) clearance from the U.S. Food and Drug Administration in December 2011. NinePoint launched its lead product, the NvisionVLE™ Imaging System, in the U.S. in May 2013. Backed by Third Rock Ventures and Prospect Venture Partners, NinePoint is headquartered in Cambridge, Mass. For more information, please visit [www.ninepointmedical.com](http://www.ninepointmedical.com).

###